Related Experiment Video
Updated: Apr 2, 2026
05:49
Protein Engineering by Yeast Surface Display
Published on: November 29, 2024
4.1K
De Novo Design and Directed Evolution Refinement of Mirror-Image Protein Binders Targeting Interleukin-4
Liqing Xu1,2,3,4, Yuxiang Ren5, Tongyue Wang5
1College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang, China.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|March 31, 2026
Summary
Researchers engineered a novel D-protein inhibitor targeting human interleukin-4 (IL-4) for allergic diseases and cancer. This D-protein demonstrates high stability and potent inhibition, offering a promising therapeutic platform.
Area of Science:
- Biochemistry
- Molecular Biology
- Drug Discovery
Background:
- Human interleukin-4 (IL-4) is a key target for allergic diseases and cancer.
- Existing biologics targeting IL-4 have limitations in stability and specificity.
Purpose of the Study:
- To engineer a novel D-protein inhibitor targeting human IL-4.
- To overcome stability and specificity limitations of current IL-4 biologics.
Main Methods:
- Combined de novo computational design with directed evolution.
- Utilized WALTZ-guided aggregation prediction for optimization.
- Designed epitope-specific inhibitors against D-IL-4 structure.
Main Results:
- Developed D-18252-evo, a D-protein inhibitor with nanomolar affinity for IL-4.
- Demonstrated effective blocking of IL-4 receptor engagement.
- Confirmed potent inhibition of IL-4-induced STAT6 phosphorylation and cell proliferation.
- Showcased exceptional biophysical properties: high thermal stability and proteolytic resistance.
Conclusions:
- Established a scalable framework for generating robust mirror-image therapeutics.
- Positioned D-proteins as a next-generation platform for cytokine-driven disorders.
- Highlighted enhanced stability and targeted efficacy of D-protein inhibitors.
